FIGURE 49.1 Bone mineral density (BMD)–fracture threshold relations comparing the placebo arms of two risedronate glucocorticoid trials (containing 306 total patients with 30 incident fractures) with three risedronate trials of postmenopausal osteoporosis at both the lumbar spine (A) and the femoral neck (B). Rate of fractures was approximately six-fold higher among the glucocorticoid users compared to nonusers after adjustment for covariates. Source: reproduced from T. P. van Staa, R. F. Laan, I. P. Barton, S. Cohen, D. M. Reid, and C. Cooper, Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48, 3224–3229 (2003), with permission of Wiley-Liss, Inc., a subsidiary of John Wiley & Sons, Inc. 2
Your consent to our cookies if you continue to use this website.